Summary – In this episode of Life Science Success, my guest is Ross Youngs. Ross is the CEO and Founder of Biosortia Pharmaceutical. Ross is working to Provide previously unobtainable drug-like small molecules directly from microbiomes.
Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing (December 21, 2022) BOULDER, Colo.–(BUSINESS WIRE)–Enveda Biosciences today announced that it has closed a $68-million equity and debt financing. Dimension led the Series B round, which included participation by multiple new institutional investors, including FPV, Jazz Venture Partners, Level Ventures, Amino Collective, Allen &
Wave Life Sciences to receive $170M upfront in new partnership with GSK to develop a large number of candidates (December 13, 2022) | By Tyler Patchen. Wave Life Sciences has picked up another deal with a major pharma company. The Massachusetts-based biotech on Tuesday announced it has entered a strategic collaboration with GSK to advance
Amgen Is Said to Agree to Buy Horizon at $26 Billion Value (December 12, 2022) | By Katie Roof, Michelle F Davis, and Dinesh Nair. Amgen agrees to pay around $116.5 for each Horizon share Sanofi, Johnson & Johnson both walked away from discussions Amgen Inc. has agreed to buy Horizon Therapeutics Plc at a
Paragon Therapeutics Launches First Spinout, Apogee Therapeutics, to Advance Novel Therapies for Inflammatory and Immunological Conditions (December 07, 2022) | By Paragon Therapeutics. Apogee emerges with $169 million to expand team and progress lead program APG777 into the clinic Milestone validates Paragon’s strategy to rapidly deliver best-in-class biologic therapies to patients WALTHAM, Mass., Dec. 7,
